Immunotherapy drug combo helps extend lives of people with metastatic melanoma
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to widely used immunotherapy drugs called PD-1 inhibitors.In clinical trials, the investigators found that the combination therapy could extend the amount of time patients live without their cancer worsening, known as progression-free survival, and that it helps overcome their resistance to prior immunotherapies — which would allow more people to benefit from the treatment.The study evaluated the use of the imm...
Source: UCLA Newsroom: Health Sciences - August 18, 2023 Category: Universities & Medical Training Source Type: news
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships
In its mission to make "cure" a reality for cancer patients everywhere, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2023 Fellowships. MILWAUKEE, Aug. 16, 2023 /PRNewswire-PRWeb/ -- In its mission to make "cure" a reality for... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2023 Category: Pharmaceuticals Tags: AWD NPT Source Type: news
Study shows promise of immunotherapy treatment for penile cancer
Yale researchers finds that the use of immune checkpoint inhibitors could expand limited treatment options for some patients with a rare form of penile cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - August 15, 2023 Category: Universities & Medical Training Source Type: news
Cancer-infecting virus & #039;warms up & #039; cold tumors and improves immunotherapy
Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, according to a new study in the Journal of Experimental Medicine led by University of Pittsburgh and UPMC researchers. The results pave the way for clinical trials combining oncolytic viruses with immunotherapy. (Source: World Pharma News)
Source: World Pharma News - August 15, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Immune-Based Cancer Drugs Offer Hope Against Penile Cancers
TUESDAY, Aug. 15, 2023 -- Men who have a rare cancer of the penis may have a new treatment option, according to researchers who found promise in immunotherapy.
This new study focused on cancer that was locally advanced or had spread... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2023 Category: General Medicine Source Type: news
Peanut Oral Immunotherapy Effective for Children Under 12 Months
MONDAY, Aug. 14, 2023 -- Peanut oral immunotherapy (OIT) can induce desensitization to peanuts in children younger than 12 months of age, according to research published online July 13 in the Journal of Allergy and Clinical Immunology: In... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 14, 2023 Category: Pharmaceuticals Source Type: news
Hope for blood cancer patients after immunotherapy drug trials show 'groundbreaking results'
The Christie Foundation Trust in Manchester is running around 30 clinical trials for a set of drugs that are so cutting-edge that they don't yet have names (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2023 Category: Consumer Health News Source Type: news
Immune Issues After Adjuvant Anti –PD-1 Therapy in Melanoma Immune Issues After Adjuvant Anti –PD-1 Therapy in Melanoma
Chronic immune-related adverse events often persist years after adjuvant anti –PD-1 immunotherapy for high-risk melanoma and may require prolonged monitoring and management, researchers say.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration.
Avenge Bio, a biotechnology company working on a new treatment platform for immunotherapy, announced it was granted the designation for its drug AVB-001 in June. It is currently enrolling patients in ongoing phase 1 and phase 2 clinical trials for the treatment of advanced ovarian cancer, primary peritoneal mesothelioma and fallopian tube cancer.
AVB-001 is a new treatment being developed by Avenge Bio using its LOCOcyte immunotherapy platform to treat solid tumors. It’s a first-in-human, si...
Source: Asbestos and Mesothelioma News - August 9, 2023 Category: Environmental Health Authors: Lynette Zilio Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Study Confirms That Exposure Therapy in Infancy Can Stop Peanut Allergy
MONDAY, Aug. 7, 2023 -- Early and gradual exposure to peanuts under medical supervision curbed infants ' allergies, according to a new study.
While researchers had seen that peanut oral immunotherapy was well tolerated by toddlers, this research... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2023 Category: General Medicine Source Type: news
Michael W. Fanger, Renowned Immunologist Who Paved the Way to Cancer Immunotherapy, Dies
Michael W. Fanger, PhD, professor emeritus, former chair of the Department of Microbiology and Immunology at Geisel School of Medicine, and entrepreneur died Tuesday, August 1. He was 83 years old. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - August 3, 2023 Category: Hospital Management Authors: Susan Green Tags: News Michael Fanger Source Type: news
PET/CT improves survival outcomes in patients with HNSCC
PET/CT scans during annual follow-up visits for patients treated for head an...Read more on AuntMinnie.comRelated Reading:
Do PET/CT reports contain riddles for oncologists?
PET/CT shows promise predicting outcomes in head, neck cancer
PET radiomics tailor head/neck cancer treatment
RT + immunotherapy = head/neck cancer treatment option
CT lung screening can catch recurring head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 1, 2023 Category: Radiology Source Type: news
Episode 1: Immunotherapy in TNBC: What's New, What's Next? Episode 1: Immunotherapy in TNBC: What's New, What's Next?
Join experts Drs Kevin Kalinsky and Heather McArthur as they discuss the latest studies guiding their decisions when treating patients with TNBC in clinic.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
RFS Failed as Endpoint in Adjuvant Immunotherapy Trials RFS Failed as Endpoint in Adjuvant Immunotherapy Trials
A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
